- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02739711
Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients With Myocardial Infarction and No-reflow (REVERSE-FLOW)
May 23, 2023 updated by: Prof. Dr. med. Ingo Eitel, University of Luebeck
Prospective RandomizEd Study Comparing Glycoprotein IIb/IIIa Inhibitors VERsus Standard Therapy in patientS With Myocardial Infarction and Angiographic Evidence of No-reFLOW
Aim of the study is to examine the effects of glycoprotein IIb/IIIa inhibitors on reperfusion success assessed by cardiac magnetic resonance imaging in patients with myocardial infarction and angiographic evidence of no-reflow.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Luebeck, Germany, 23538
- Recruiting
- University of Luebeck
-
Contact:
- Ingo Eitel
- Email: ingo.eitel@uksh.de
-
Principal Investigator:
- Ingo Eitel
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ST-elevation myocardial infarction and non-ST-elevation myocardial infarction <48 h after symptom onset
- Angiographic evidence of no-reflow (Thrombolysis in Myocardial Infarction-flow grade ≤2) after primary percutaneous coronary intervention
- Age ≥18 years
- Informed consent
Exclusion Criteria:
- ST-elevation myocardial infarction and non-ST-elevation myocardial infarction patients with Thrombolysis in Myocardial Infarction-flow 3 after primary percutaneous coronary intervention
- Age ≤18 years
- Known pregnancy, breast-feeding or intend to become pregnant during the study period
- Contraindication for treatment with platelet inhibitors
- Known allergy to glycoprotein IIb/IIIa inhibitors, aspirin, or heparin
- Active peptic gastric or duodenal ulcer
- History of major surgery (including intracranial or intraspinal) <4 weeks
- Active bleeding or bleeding diathesis
- Stroke <2 years (ischemic and hemorrhagic)
- Known coagulation defect or relevant thrombocytopenia
- Arteriovenous malformations or aneurysm
- Severe liver insufficiency
- Renal insufficiency requiring dialysis
- Uncontrolled hypertension
- Hypertensive retinopathy
- Vasculitis
- Fibrinolysis <12 hours
- Contraindication for cardiac magnetic resonance imaging at study entry
- Patients without informed consent
- Participation in another trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Glycoprotein IIb/IIIa inhibitor
Glycoprotein IIb/IIIa inhibitor administration
|
Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
|
No Intervention: Standard therapy
No glycoprotein IIb/IIIa inhibitors
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Infarct size assessed by cardiac magnetic resonance imaging
Time Frame: Day 1-10 after myocardial infarction
|
Day 1-10 after myocardial infarction
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2016
Primary Completion (Estimated)
December 1, 2023
Study Completion (Estimated)
December 1, 2025
Study Registration Dates
First Submitted
April 13, 2016
First Submitted That Met QC Criteria
April 13, 2016
First Posted (Estimated)
April 15, 2016
Study Record Updates
Last Update Posted (Actual)
May 25, 2023
Last Update Submitted That Met QC Criteria
May 23, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Protective Agents
- Adjuvants, Immunologic
- Antibiotics, Antineoplastic
- Interferon Inducers
- Radiation-Protective Agents
- polysaccharide-K
Other Study ID Numbers
- AZ 15-259
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myocardial Infarction
-
Henry Ford Health SystemAbiomed Inc.Enrolling by invitationAcute Myocardial Infarction | Cardiogenic Shock | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial Infarction | NSTEMI | Acute Myocardial Infarction With ST Elevation | Acute Myocardial Infarction of Right Ventricle (Disorder) | Acute Myocardial Infarction of Left VentricleUnited States
-
Jordan Collaborating Cardiology GroupCardiovascular Academy GroupTerminatedTriggers of Acute Myocardial Infarction | Time of Onset of Acute Myocardial Infarction | Long-term Prognosis After Acute Myocardial InfarctionJordan
-
Recardio, Inc.CompletedAcute Myocardial Infarction | STEMI - ST Elevation Myocardial Infarction | Acute Myocardial IschemiaNetherlands, Hungary, Austria, Poland, Belgium
-
Yuan's General HospitalKaohsiung Veterans General Hospital.; Sin-Lau HospitalUnknownAcute Myocardial Infarction, of Inferolateral Wall | Acute Myocardial Infarction, of Inferoposterior WallTaiwan
-
Medical Center of South ArkansasWithdrawnAcute Coronary Syndrome | Acute ST Segment Elevation Myocardial InfarctionUnited States
-
Aristotle University Of ThessalonikiRecruitingCardiovascular Diseases | Acute Coronary Syndrome | Acute Myocardial Infarction | Metabolic DisturbanceGreece
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
Sheba Medical CenterCompletedNon ST Elevation Myocardial Infarction | Acute Coronary SyndromesIsrael
-
Medstar Health Research InstituteWithdrawnST-elevation Myocardial Infarction | Acute Myocardial InfarctionUnited States
-
Hennepin Healthcare Research InstituteSiemens HealthineersActive, not recruitingAcute Coronary Syndrome | Acute Myocardial InfarctionUnited States
Clinical Trials on Glycoprotein IIb/IIIa inhibitors
-
TC Erciyes UniversityCompleted
-
Yonsei UniversityISU ABXIS (Korea pharmaceutical company)CompletedMyocardial InfarctionKorea, Republic of
-
Seoul National University HospitalSeoul National University Bundang HospitalUnknownMyocardial Infarction | AngioplastyKorea, Republic of
-
Marco ValgimigliUnknownMyocardial InfarctionItaly
-
Hospital AvicenneTerminated
-
Università degli Studi di FerraraCompletedAngioplasty, Transluminal, Percutaneous CoronaryItaly
-
1ST Biotherapeutics, Inc.Merck Sharp & Dohme LLCRecruitingAdvanced Solid TumorUnited States
-
AVM Biotechnology IncAvailableCancer | Breast Cancer | Glioblastoma | Gastric Cancer | Pancreatic Cancer | Hodgkin Lymphoma | Ovarian Cancer | Prostate Cancer | Acute Leukemia | Non-hodgkin Lymphoma | Squamous Cell Carcinoma | Tumor, Solid | Tumor, Brain | Spindle Cell Sarcoma
-
Hoffmann-La RocheCompleted
-
PfizerCompletedAtopic DermatitisSpain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy